IBA Inc

Millbury, MA, United States
Millbury, MA, United States

Time filter

Source Type

News Article | May 10, 2017
Site: globenewswire.com

Louvain-La-Neuve, Belgium, May 10, 2017 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today provides a trading update for the first quarter ending 31 March 2017. Olivier Legrain, Chief Executive Officer of IBA, commented: "We are pleased to have made good progress in this first quarter of 2017 and are on track to meet our growth targets. Dosimetry has seen a good recovery across all regions and is now positively contributing to our REBIT. Our production expansion and regionalization strategy to meet growing global demand continues to be rolled out and we are currently installing eight projects across the globe and getting ready to install another 17 internationally. "In Proton Therapy, however, several recent delays in project execution caused by customer building delays lead us to slightly adjust our full year guidance for 2017. While our guidance on revenue growth remains unchanged at around 15% to 20%, the project execution delays impact our revenue recognition and, to some extent, our operational leverage. Due to this, we revise our guidance on REBIT to between 10% and 12% for 2017, and around 13% for 2018. "We are confident in the strong prospects for IBA in 2017 and beyond due to our growth strategy, the significant market potential in proton therapy and our focus on maintaining the world's leading proton therapy offering." IBA reported the following segmental trends and news during the first quarter of 2017: Proton therapy's penetration of the radiation therapy market continues to grow due to increasing interest from the clinical community, affordability and technological advances. To keep ahead of and to lead this growth, IBA continues to scale up production capacity, including investment in a new superconducting synchrocyclotron assembly line (for Proteus®ONE*), and a new customer center, with an expected further combined CAPEX of about EUR 16 million, of which around EUR 10 million will be invested in 2017. The Company is also recruiting an additional 200 engineers and qualified staff, worldwide, through 2017. IBA has a high backlog of EUR 316 million and the sustainable revenue source from service and maintenance contracts now represents EUR 673 million of revenue over the next 10-15 years. IBA expects to achieve revenue growth of between 15% to 20% in 2017 and double digit thereafter. The Company expects its operating margin to be 10% to 12% in 2017, increasing to around 13% by 2018 and stabilizing at around 15% by 2020. IBA is planning to maintain a dividend payout ratio of 30%. This guidance is not only based upon the continued expected growth of the proton therapy market but also the balance between the economies of scale that we can achieve at a higher production rate. In addition, the growing importance of service revenue versus the increased demand driven by the equipment price tag reduction in the proton therapy market and our continued investment in R&D and software capabilities are anticipated to be contributing factors. In accordance with the Royal Decree of 14 November 2007, IBA indicates that this Trading Update has been prepared by the Chief Executive Officer (CEO) and the Chief Financial Officer (CFO). About IBA IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com *Proteus®ONE and Proteus®PLUS are brand names of Proteus 235 For further information, please contact:


News Article | May 18, 2017
Site: www.prweb.com

Irving Burton Associates (IBA), a leading technology consulting services firm, is pleased to announce that it has been appraised at Level 3 of the CMMI Institute’s Capability Maturity Model Integration (CMMI)® for both Development and Services. The appraisal was performed independently by Acuity Inc. CMMI® is a capability improvement approach that boast decades of successful results. This proven methodology provides organizations with the essential elements of effective processes that ultimately improve their performance. “This appraisal is exemplary of IBA’s commitment to the success of our federal clients” said Karthik Srinivasan, Senior Vice President at IBA. “A successful Maturity Level 3 appraisal confirms our organization-wide dedication to providing reliable, predictable processes that deliver innovative solutions and services on time and within budget. The team at IBA has always been passionate about delivering solutions and services that meet and exceed industry standards – this appraisal is an excellent affirmation of our continuing efforts.” An appraisal at Maturity Level 3 indicates that IBA is performing at a “defined” level. At this level, processes are well characterized and understood, and are described in standards, procedures, tools, and methods. The organization’s set of standard processes, which is the basis for Maturity Level 3, is established and continues to improve over time. About CMMI The CMMI® Institute, a subsidiary of Carnegie Mellon University, is dedicated to elevating organizational performance through best-in-class solutions to real-world challenges. The Institute is the home of the Capability Maturity Model Integration (CMMI)® for Development, Services, and Acquisition; the People Capability Maturity Model; and the Data Management Maturity Model (DMM)SM, which are capability improvement models that create high-performance, high-maturity cultures. The models are used in thousands of organizations worldwide to deliver business results that serve as differentiators in the global market. About IBA IBA is a woman-owned service provider headquartered in Falls Church, VA, with regional offices in San Antonio, TX, Frederick, MD, and Washington, DC. This leading technology consulting services firm has over 37 years of experience delivering innovative work on the nation’s largest business and Health IT projects. IBA’s teams specialize in Agile development, Agile transformation, Enterprise IT, Mobile apps, program management and financial services. To learn more about IBA’s capabilities, please visit http://www.ibacorp.us.


News Article | June 15, 2017
Site: www.prnewswire.com

IBA Group (http://www.ibagroupit.com) wird in der Kategorie "Leaders" aufgeführt und als Super Star of the Global Outsourcing 100 for Sustained Excellence und als Top Company (‚Star') für Kundenreferenzen, Preise & Zertifizierungen, Innovationsprogramme sowie Programme für soziale unternehmerische Verantwortung gewürdigt. Die Summe der Punktezahl in diesen Kategorien entscheidet über die Aufnahme in die Liste. Sämtliche Unternehmen auf der Liste haben sich weltweit besonders verdient gemacht. ‚Stars' bekommen alle Unternehmen, die sich in einer oder mehr Bewertungskategorien hervorgetan haben. Sergei Levteev, Vorsitzender der IBA Group, fügte hinzu: "IBA Group hat es im fünften Jahr in Folge in der Kategorie ‚Leader' in die Liste ‚Global Outsourcing 100' geschafft.  Wir haben wiederholt unser Bemühen um die höchsten Standards bei Leistung, Kundenservice, Innovation und sozialer Verantwortung unter Beweis gestellt. Die Liste ‚Global Outsourcing 100' bietet einen konsistenten Vergleich, wie ein Unternehmen gegenüber anderen Branchenteilnehmern abschneidet. Dieses Jahr hat IBA Group nicht nur seine vier ‚Stars' vom letzten Jahr verteidigt, sondern auch den Preis als Superstar der Global Outsourcing 100 für nachhaltige Spitzenleistung erhalten. Ich glaube, das ist selbstredend. Wir ruhen uns aber auf diesem Erfolg nicht aus. Wir werden weiter arbeiten, entwickeln und uns neue Ziele und Maßstäbe setzen."


News Article | June 15, 2017
Site: www.prnewswire.com

IBA Group - http://www.ibagroupit.com - se voit inclus dans la catégorie des « Leaders » et est reconnu comme « Super étoile » du Global Outsourcing 100 pour son excellence soutenue et comme Meilleure compagnie (« étoile ») en termes de références clientèle, prix et certifications, programmes pour l'innovation et programmes pour la responsabilité sociétale des entreprises. Actuellement dans sa 11e année, le Global Outsourcing 100 reconnaît les meilleurs prestataires de services d'externalisation au monde. Les entreprises sont d'abord organisées en fonction des critères « Leader » ou « Étoile montante », puis évaluées à l'aune des cinq catégories de jugement suivantes : taille et croissance, références client, prix et certifications, programmes pour l'innovation et responsabilité sociétale des entreprises (RSE). « Les acheteurs comprennent qu'il y a des centaines de prestataires de services et de consultants qualifiés sur le marché, mais ce qu'ils doivent véritablement comprendre désormais est ce qui fait de chacun une entité exceptionnelle », a déclaré la PDG d'IAOP, Debi Hamill. « C'est précisément ce que viennent de faire les listes du Global Outsourcing 100 et des Meilleurs consultants au monde. Nous sommes heureux de reconnaître IBA Group parmi les entreprises aux plus hauts scores en termes de références clientèle, prix d'entreprise et certifications, programmes pour l'innovation et RSE, et comme « super étoile » de Global Outsourcing 100 en termes d'excellence soutenue. Sergei Levteev, président d'IBA Group, a ajouté : « IBA Group a été catalogué sur la liste des entreprises du Global Outsourcing 100 dans la catégorie 'Leader' pour la cinquième année consécutive. Nous avons démontré sans relâche notre engagement à l'égard des plus hautes normes d'excellence, de service à la clientèle, d'innovation et de responsabilité sociétale des entreprises. Le Global Outsourcing 100 donne une vision complète de la façon dont une entreprise se comporte par rapport à ses homologues du secteur. Cette année, IBA Group n'a pas seulement confirmé ses quatre 'étoiles' de l'année dernière, mais a également reçu une récompense de « Super étoile » de la part du Global Outsourcing 100 pour l'excellence soutenue. Je crois que cela est assez éloquent. Cependant, ce n'est le moment de nous reposer sur nos lauriers. Nous allons continuer à travailler, à nous développer et lutter au nom de nouveaux objectifs et de nouveaux exploits. »


News Article | June 15, 2017
Site: www.prnewswire.com

IBA Group - http://www.ibagroupit.com - is included in the Leaders category and recognized as a Super Star of the Global Outsourcing 100 for Sustained Excellence and as a Top Company ('star') for Customer References, Awards & Certifications, Programs for Innovation, and Programs for Corporate Social Responsibility. Now in its 11th year, The Global Outsourcing 100 recognizes the world's best outsourcing service providers. Companies are first organized by Leader or Rising Star criteria and then evaluated based on the following five judging categories: Size and Growth, Customer References, Awards and Certifications, Programs for Innovation, and Corporate Social Responsibility (CSR). The aggregate scores from the areas above determine inclusion on the list. All companies included on the list have demonstrated their global excellence; 'stars' are awarded to all companies distinguishing themselves in one or more judging category. "Buyers understand there are hundreds of qualified service providers and advisors out there, but what they really need to understand now is what makes each one exceptional," said IAOP CEO, Debi Hamill. "The Global Outsourcing 100 and World's Best Advisors lists have done just that. We are proud to recognize IBA Group for being among the highest rated companies in customer references, company awards and certifications, programs for innovation, and CSR, and as a super star of the Global Outsourcing 100 for Sustained Excellence." Sergei Levteev, IBA Group Chairman, added: "IBA Group has been listed among The Global Outsourcing 100 companies in the Leader category for the fifth consecutive year.  We have repeatedly demonstrated commitment to the highest standards of excellence, customer service, innovation, and social responsibility. The Global Outsourcing 100 gives a consistent view of how a company is performing against industry peers. This year, IBA Group has not only confirmed its four 'stars' from last year, but was also awarded a Super Star of the Global Outsourcing 100 for Sustained Excellence. I believe it speaks for itself. However, it is not the time to rest on the laurels. We will keep working, developing, and striving for new goals and heights." See the 2017 Global Outsourcing 100 list at


News Article | June 15, 2017
Site: www.prnewswire.co.uk

IBA Group - http://www.ibagroupit.com - is included in the Leaders category and recognized as a Super Star of the Global Outsourcing 100 for Sustained Excellence and as a Top Company ('star') for Customer References, Awards & Certifications, Programs for Innovation, and Programs for Corporate Social Responsibility. Now in its 11th year, The Global Outsourcing 100 recognizes the world's best outsourcing service providers. Companies are first organized by Leader or Rising Star criteria and then evaluated based on the following five judging categories: Size and Growth, Customer References, Awards and Certifications, Programs for Innovation, and Corporate Social Responsibility (CSR). The aggregate scores from the areas above determine inclusion on the list. All companies included on the list have demonstrated their global excellence; 'stars' are awarded to all companies distinguishing themselves in one or more judging category. "Buyers understand there are hundreds of qualified service providers and advisors out there, but what they really need to understand now is what makes each one exceptional," said IAOP CEO, Debi Hamill. "The Global Outsourcing 100 and World's Best Advisors lists have done just that. We are proud to recognize IBA Group for being among the highest rated companies in customer references, company awards and certifications, programs for innovation, and CSR, and as a super star of the Global Outsourcing 100 for Sustained Excellence." Sergei Levteev, IBA Group Chairman, added: "IBA Group has been listed among The Global Outsourcing 100 companies in the Leader category for the fifth consecutive year.  We have repeatedly demonstrated commitment to the highest standards of excellence, customer service, innovation, and social responsibility. The Global Outsourcing 100 gives a consistent view of how a company is performing against industry peers. This year, IBA Group has not only confirmed its four 'stars' from last year, but was also awarded a Super Star of the Global Outsourcing 100 for Sustained Excellence. I believe it speaks for itself. However, it is not the time to rest on the laurels. We will keep working, developing, and striving for new goals and heights." See the 2017 Global Outsourcing 100 list at


News Article | December 13, 2016
Site: globenewswire.com

IBA signs two new Proteus®ONE contracts with Proton Partners International Louvain-La-Neuve, Belgium, 13 December 2016 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed two new contracts with Proton Partners International (PPI), to install two Proteus®ONE* compact proton therapy solutions in Reading and an undisclosed site in the UK. The contracts are effective as of today. The contracted Proteus®ONE solutions include Pencil Beam Scanning (PBS) and Cone Beam CT (CBCT) capabilities making Proteus®ONE the only compact solution ready for adaptive treatment. The contracts also include a maintenance agreement. The typical end-user price for a Proteus®ONE solution with a maintenance contract is between EUR 35 and 40 million. These new centers will be the fifth and sixth that IBA will install for PPI. Previously-ordered centers by PPI are currently being installed in Wales (Newport), in England (Northumberland and London) and in Abu Dhabi, UAE. These latest contracted Proteus®ONE will be the 15th and 16th installation of IBA's compact single-room proton therapy solution, globally. IBA has now sold 45 proton therapy centers worldwide. These projects are a result of the framework agreement with Philips that has been in place since September 2014, demonstrating the benefit of this relationship in bringing new international contracts to fruition. Olivier Legrain, Chief Executive Officer of IBA, commented: "We are delighted to partner with PPI, the institution that leads proton therapy penetration in UK and in the United Arab Emirates. PPI's choice of IBA and our compact solution demonstrates the increasing demand for this cutting edge treatment modality. At present, proton therapy represents only 1% of all radiotherapy treatments, however, studies estimate that 20% of patients treated by radiotherapy would benefit from being treated with proton therapy." Mike Moran, Chief Executive Officer of Proton Partners International Limited, added: "We are very pleased to further expand our collaboration with IBA following the highly professional support and responsiveness that it has demonstrated to date. Cancer incidence is rising dramatically, globally, and more innovation is needed to deal with this disease. Our strategy of building a strong international network of proton therapy centers will guarantee high-quality treatment throughout our network, enabling more patients to benefit from cutting-edge proton therapy. Every cancer patient in UK deserves the best possible care without needing to travel far." About Proteus®ONE Proteus®ONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. Proteus®ONE is smaller, more affordable, easier to install and to operate. It is ultimately easier to finance, making this advanced radiation therapy modality available to more institutions and patients worldwide. Proteus®ONE makes proton therapy easy. * Proteus®ONE is the brand name of Proteus®235 in the US and Europe and a certified product in Japan. About IBA IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com About Proton Partners International Limited Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation's cancer programme, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors have committed to almost £100m equity finance in the company. Professor Gordon McVie, Clinical Research Adviser to the FIRC Institute of Molecular Oncology (IFOM), is non-executive chairman and Professor Karol Sikora is chief medical officer to the company. The Welsh Government's Life Sciences Investment Fund is a key investor in Proton Partners International. For more information on Proton Partners, please visit: www.proton-int.com For further information, please contact:


News Article | December 15, 2016
Site: globenewswire.com

Louvain-la-Neuve, Belgium, December 15, 2016 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, communicates today the basic and additional data as per Article 15 §1 al.1 of the Transparency Law, following its capital increase (further to exercises and cancellations of stock options) dated December 15, 2016. Data concerning transparency Heading II of the law of May 2, 2007 and the Royal Decree of February 14, 2008 Communication of the basic data as per Article 15 §1 al.1 of the Law Communication of the additional data as per Article 15 §1 al.2 of the Law Statutory thresholds as per Article 18 of the Law The applicable thresholds as follows: three percent, five percent, ten percent, fifteen percent and so on by brackets of five percent. About IBA IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com . For more information, please contact IBA Caroline Hardy Corporate Legal Counsel +32 10 201 159 caroline.hardy@iba-group.com


News Article | February 20, 2017
Site: globenewswire.com

IBA Selected to Install New Proton Therapy Center in Charleroi, Belgium New Proteus®One installation to be dedicated to research and development in collaboration with the Wallonia Region government and four leading Belgian universities Louvain-la-Neuve, Belgium, February 20, 2017 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces today that it has been selected as the preferred vendor by four leading universities of Brussels (ULB), Liège (Ulg), Mons (UMons) and Namur (UNamur), alongside the Wallonia Region government, to install a Proteus®ONE* solution, IBA's single-room compact proton therapy system, in Charleroi, Belgium. IBA was selected following a comprehensive European public tender process and expects to sign a final contract in the coming weeks, after expiration of the applicable waiting period. The new center will be dedicated primarily to the research and development of new proton therapy applications and techniques in order to extend the range of proton therapy used in the treatment of cancer. The center, which will also treat patients, will be located in Charleroi and is expected to be operational in 2020. The Wallonia Region will invest a total of EUR 47 million in this research project, which will include the IBA technology, research program, maintenance contract as well as related equipment. Olivier Legrain, Chief Executive Officer of IBA commented: "We are delighted to have been selected to build a proton therapy center dedicated to R&D, demonstrating that Belgium has all the scientific, clinical and technological expertise required to advance this significant technology in the fight against cancer. Not only will this research and development center enable IBA and the Belgian universities to test and develop new generation technologies to fight cancer, it will also develop and anchor industrial expertise shared by a network of local companies. We are committed to supporting these universities in providing high-quality cancer treatment to more patients in Belgium." About IBA IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com *Proteus®ONE is a brand name of Proteus 235 For further information, please contact:


News Article | December 6, 2016
Site: www.prnewswire.com

PRAGUE, December 6, 2016 /PRNewswire/ -- Software Magazine Ranks IBA Group as one of the World's Largest Software Companies in 2016 IBA Group http://www.ibagroupit.com announces its inclusion in Software Magazine's Software 500 ranking of the world's largest software and service...

Loading IBA Inc collaborators
Loading IBA Inc collaborators